Every major scientific breakthrough begins with a simple belief: that patients deserve a better future. As we gather at the World Conference on Lung Cancer (WCLC) 2026 in Seoul, I am inspired by how far the lung cancer community has come, and even more energised by what lies ahead. The future of lung cancer care is being shaped today through earlier diagnosis, improved access to care and more personalised treatment approaches enabled by technology and scientific innovation. This year's congress brings together some of the most promising advances in lung cancer research. Beyond the science itself, these developments offer something even more meaningful: hope that more people can live longer, healthier lives with their families and communities. For Vietnam, the opportunity is clear. Too many patients are still diagnosed when the disease has already progressed. To truly change outcomes, innovation must go hand in hand with stronger early detection efforts, timely diagnosis and access, and seamless navigation through the healthcare system. At AstraZeneca, we believe scientific breakthroughs achieve their greatest impact when they reach patients earlier. This is why we continue working with healthcare partners to strengthen early detection and patient navigation, helping more people access the right care at the right time. As we head into WCLC 2026, our leaders share their vision for how continued scientific progress could transform what is possible by 2040, as we work towards our ambition to eliminate cancer as a cause of death. The future is not something we wait for. Together, it is something we build. #WCLC2026 #LungCancer #EarlyDetection #Vietnam #HealthEquity

Until recently, thyroid cancer was one of the fastest-growing cancer diagnoses in the U.S., largely due to more thyroid tumors being discovered during imaging exams performed for other medical conditions. With stricter diagnostic criteria, however, incidence rates have declined by 1.4% annually from 2013 to 2022. Two important facts to know: • Thyroid cancer is most commonly diagnosed around age 51. • Women are approximately three times more likely to develop thyroid cancer than men. (Source: American Cancer Society) This Thyroid Cancer Awareness Month, help raise awareness about the importance of early detection and timely diagnosis. #ThyroidCancerAwareness #ThyroidHealth #MedicalImaging #SourceRay #CancerPrevention

Despite major advances that have made advanced lung cancer more treatable, fewer than half of older patients with the disease receive treatment — a gap experts say begins with late diagnoses and extends to barriers that persist even after cancer is found. Read more: https://lnkd.in/eWJv6c7T

Understanding how treatment fits into patients’ lives is an important part of improving cancer care. At #WCLC26, we’re sharing new research focused on helping to improve the treatment experience of people living with EGFR-mutated lung cancer. These findings reflect our ongoing commitment to advancing how treatment is delivered as we push for better outcomes and better experiences for the people counting on them. Learn more about the findings: https://ow.ly/bSlJ50ZNRIT

From pioneering research to developing next-generation therapies, our commitment to hematology runs deep. Every three minutes, someone is diagnosed with a form of blood cancer in the U.S. Each diagnosis represents a parent, family member, a colleague or friend navigating this change. Join us this month as we honor the strength of the blood cancer community, share stories of hope and reinforce our promise to pursue better patient outcomes. https://bit.ly/3SESD5y #BloodCancerAwarenessMonth #OneBMS

What keeps me going in research - those moments when early data hint we're onto something real. And as a hematologist, I know what that can mean for a patient. This Blood Cancer Awareness Month, I’m especially mindful of the important work that my fellow researchers at Bristol Myers Squibb are doing to bridge discovery and development through translational medicine. By integrating biomarker, molecular and clinical insights, these teams are helping us better understand disease, make more informed decisions earlier and advance research that aims to bring us closer to our goal of improving outcomes for patients.      It’s a powerful example of how translational science is helping connect discoveries in the lab with insights that can inform meaningful advances for people affected by blood cancer and other serious diseases.      https://lnkd.in/gSYS-eqq      #BMS_Employee #BloodCancerAwarenessMonth  

At #WCLC26, we're sharing new data that reflects our ongoing commitment to improving outcomes in EGFR-mutated lung cancer. Each study builds on years of scientific progress and is helping us continue to raise expectations for people living with this disease and shape the future of cancer care. Explore the research we’re presenting at WCLC: https://ow.ly/xiE850ZMMjy

Blood cancer outcomes have changed dramatically over the past several decades. Five-year relative survival rates have climbed significantly since the 1970s, driven by more effective therapies, earlier and more precise diagnostics, and better tools to monitor disease over time. This #BloodCancerAwarenessMonth, explore the full data behind this progress — and what it means for patients today — from our partners at Blood Cancer United. https://lnkd.in/erRub_45 clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: https://rb.gy/8tju9y

At AstraZeneca, I’m often reminded that supporting people affected by lung cancer means looking beyond treatment alone. To improve outcomes, we need to consider the full patient journey — from screening and earlier detection to faster diagnosis and the use of technology that can help more patients receive the right care sooner. As WCLC approaches, what are your hopes for the future of lung cancer care? #WCLC26

At AstraZeneca, I’m often reminded that supporting people affected by lung cancer means looking beyond treatment alone. To improve outcomes, we need to consider the full patient journey — from screening and earlier detection to faster diagnosis and the use of technology that can help more patients receive the right care sooner. As WCLC approaches, what are your hopes for the future of lung cancer care? #WCLC26